The Foundation for Innovative New Diagnostics (FIND) announced last Friday that it has awarded grants to a number of companies to address the urgent diagnostic needs for hepatitis C virus (HCV). These grants will be used to conduct feasibility studies of various technologies that could transform HCV testing at the point of care. Mologic is among the companies receiving support to develop and validate prototype HCV core antigen (cAg) tests on their innovative rapid diagnostic test platform. Read more on the official website: